More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

The Association for Accessible Medicines, which represents generic-drug and biosimilar manufacturers in the US, put forth a blueprint to facilitate a repatriation of pharma manufacturing to the US. What does the plan recommend? A plan for...

Is the blockbuster model still in play or has the paradigm to more specialized drugs and smaller patient populations narrowed the blockbuster field? DCAT Value Chain Insights looks at which drugs, approved over the past several years, have...

The race is on to develop treatments and vaccines against COVID-19, and so is the need to assure supply of these potential drugs and vaccines. Pharma companies are leveraging their internal manufacturing networks but also partnering with...

Is drug development and the drug-review process slowing due to the novel coronavirus? What do new drug approvals and updates from the top pharmaceutical companies show? Drug development and regulatory review With the pharmaceutical industry, both...

Small molecules dominate recent new drug approvals, but how are they factoring in the recent or potential revenue gains of the top pharma companies? DCAT Value Chain Insights examines the winners and contenders among small-molecule drugs. Small...

Vaccines, historically a commoditized sector, have risen to the top of the industry's watch list as the race for a vaccine against the novel coronavirus is on. What else is on DCAT Value Chain Insights' Top 10 Watch List for Biologics and...

Although a niche area, cell and gene therapies represent an active area of investment by CDMOs/CMOs to build manufacturing capabilities as well as having new CDMOs/CMOs enter this sector. Which companies are making the moves? Building capabilities...

Nine associations, including those representing innovator and generic-drug companies and chemical manufacturers in Europe, have recommended measures to the European Commission and European Union (EU) member states to address supply issues of drugs...

European Union (EU) authorities have issued guidance to pharmaceutical companies and suppliers to provide regulatory flexibility when sourcing reagents, starting materials, intermediates, and APIs for medicines deemed crucial in treating patients...